Reactions 1704, p122 - 2 Jun 2018 Emesis and visual disorders: case report In a retrospective analysis involving 38 patients, one female patient [age not stated] was described, who developed emesis and visual disorders during treatment with crizotinib [duration of treatment to reactions onsets and outcomes not stated]. The female patient, who was diagnosed with inflammatory myofibroblastic tumors at the age of 10.6 years, received multiple chemotherapies followed by subsequent systemic therapy comprising of crizotinib [route and dosage not stated]. Her tumour responded to crizotinib treatment, but she developed emesis and visual disorders as side effects of crizotinib therapy. The patient did not report therapy related toxicities after the reduction of the crizotinib dose. About 1 year after the crizotinib treatment, her parents stopped the treatment, but it was continued again after a 2 month gap due to progression of disease. Author comment: "Due to the fact that the treatment period of our analysis was mainly before the approval of [anaplastic lymphoma kinase] inhibitors, only one patient received therapy with the [anaplastic lymphoma kinase] inhibitor crizotinib." "The tumor responded to crizotinib but the patient suffered side effects (emesis, visual disorders)." Kube S, et al. Inflammatory myofibroblastic tumors-A retrospective analysis of the Cooperative Weichteilsarkom Studiengruppe. Pediatric Blood and Cancer 65: e27012, No. 6, Jun 2018. Available from: URL: http://doi.org/10.1002/pbc.27012 - Germany 803324062 0114-9954/18/1704-0001/$14.95 Adis © 2018 Springer International Publishing AG. All rights reserved Reactions 2 Jun 2018 No. 1704
Reactions Weekly – Springer Journals
Published: Jun 2, 2018
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera